Pfizer to give Remoxy another go after 2 FDA snubs; Pain soars
This article was originally published in Scrip
Executive Summary
Shares of Pain Therapeutics soared as high as 30% on 22 October after its partner Pfizer said it would continue development of Remoxy (oxycodone) an investigational extended-release oral formulation of oxycodone intended to provide relief of moderate to severe pain requiring continuous, around-the-clock opioid treatment – a drug that has twice been rejected by the FDA.